🔗 Share this article

The initial novel therapies for gonorrhoea in decades are being described as a "significant breakthrough" in the fight against drug-resistant strains of the infection, according to health experts.

An International Challenge

Cases of gonorrhoea are increasing around the world, with estimates suggesting over 82 million instances each year. Especially elevated rates are seen in Africa and countries within the WHO's designated area, which spans from Mongolia and China to New Zealand. In England, cases have reached a all-time high, while figures across Europe in 2023 were three times higher compared to the rates from 2014.

“The approval of novel therapies for gonorrhoea is an significant and necessary advancement in the face of growing infection rates, increasing antimicrobial resistance and the very limited therapeutic options at this time.”

Medical experts are deeply concerned about the rise in drug-resistant strains. The World Health Organization has classified it as a "priority pathogen". Recent surveillance found that resistance to standard treatments like cefixime and ceftriaxone had risen sharply between 2022 and 2024.

Two New Treatment Options Secure Clearance

One new antibiotic, marketed under the name a brand name, was approved by the US FDA in mid-December for use against gonorrhoea. This disease can lead to serious health problems, including the inability to conceive. Researchers hope that specific application of this new drug will help hinder the spread of drug resistance.

Another new antibiotic, developed by the drugmaker GSK, was also approved in close succession. This medication, which is also used to treat UTIs, was demonstrated in studies to be able to combat drug-resistant strains of the gonorrhoea bacteria.

An Innovative Approach to Creation

This new treatment emerged from a innovative non-profit model for antibiotic development. The non-profit organisation GARDP worked alongside the drug firm Innoviva to bring it to fruition.

“This milestone signifies a significant shift in the management of superbug gonorrhoea, which up to this point has been outpacing medical innovation.”

Research Study Results and Worldwide Availability

According to data detailed in a prominent scientific publication, the new drug successfully treated the vast majority of cases of the STI. This puts it on an equal footing with the current standard treatment, which involves two antibiotics. The study enrolled nearly 1,000 participants from several countries including the United States, Thailand, South Africa, and European nations.

Under the terms of its development partnership, the non-profit has the authority to license and sell the drug in many regions with limited resources.

Clinicians treating patients have voiced hope. Having a one-pill regimen of this kind is seen as a "critical tool" for managing the epidemic. This is viewed as crucial to alleviate the strain of the illness for patients and to stop the proliferation of untreatable gonorrhoea worldwide.